ID | 54815 |
JaLCDOI | |
FullText URL | |
Author |
Kanazawa, Yui
Department of aPediatrics, Okayama University Hospital
Yamashita, Yuka
Clinical Research Center, Nagoya Medical Center
Fujiwara, Mitsuhiro
Department of Pediatrics, Kurashiki Central Hospital
Muraoka, Michiko
Department of aPediatrics, Okayama University Hospital
Washio, Kana
Department of aPediatrics, Okayama University Hospital
Kanamitsu, Kiichiro
Department of aPediatrics, Okayama University Hospital
Ishida, Hisashi
Department of aPediatrics, Okayama University Hospital
Nakano, Takae
Department of aPediatrics, Okayama University Hospital
Yamada, Miho
Clinical Research Center, Nagoya Medical Center
Horibe, Keizo
Clinical Research Center, Nagoya Medical Center
|
Abstract | Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10–30 of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60–75 disease-free survival; however, a relatively high relapse rate was observed (25–30 ). We report 2 patients with Stage III ALCL who relapsed 6–18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be relatively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneficial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the first diagnostic bone marrow sample.
|
Keywords | ALCL
NPM-ALK fusion
lymphoma
|
Amo Type | Case Report
|
Publication Title |
Acta Medica Okayama
|
Published Date | 2016-12
|
Volume | volume70
|
Issue | issue6
|
Publisher | Okayama University Medical School
|
Start Page | 503
|
End Page | 506
|
ISSN | 0386-300X
|
NCID | AA00508441
|
Content Type |
Journal Article
|
language |
English
|
Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School
|
File Version | publisher
|
Refereed |
True
|
PubMed ID |